ERBB2 and breast cancer: In second‐line treatment, CDK4/6 inhibitors combined with the selective estrogen receptor degrader fulvestrant for HR‐positive/HER2‐negative breast cancer were studied in three trials: PALOMA‐3, MONALEESA‐3, and MONARCH‐2.